Tag: News

  • Gwyneth Paltrow Thinks Psychedelic Drugs May Be Next Wellness Trend

    Gwyneth Paltrow Thinks Psychedelic Drugs May Be Next Wellness Trend

    Paltrow believes that ibogaine—a psychoactive substance made from a West African plant—has the potential to help the culture “evolve,”

    No one really knows what’s next in the wellness world — but according to Gwyneth Paltrow, it may be psychedelic drugs.

    In a recent interview with the New York Times, the actress and founder of the wellness brand goop was asked about what may be the next big thing. 

    “I think how psychedelics affect health and mental health and addiction will come more into the mainstream,” she told the Times. “I mean there’s undeniably some link between being in that state and being connected to some other universal cosmic something.”

    Paltrow tells the Times that she has never tried any type of psychoactive drug herself, though she said she believes that ibogaine — a psychoactive substance made from a West African plant —  has the potential to help the culture “evolve,” according to Page Six

    Paltrow told the Times that she and goop have been ahead of the curve with other trends. 

    “When we talk about something that is incendiary, I always see in six months other people starting to write about it, and 18 months later, businesses popping up around it,” she said. “It’s always confirmation to me that we’re on the right track. I mean, when I did my gluten-free cookbook in 2015, the press was super negative and there were personal attacks about what I was feeding my children and what kind of mother I am. Now the gluten-free market is huge.”

    Paltrow began goop about 10 years ago as a newsletter of sorts, and in the time since it has grown into a “modern lifestyle brand,” according to the website. 

    “We believe that the little things count, that good food is the foundation of love and wellness, that the mind/body/spirit is inextricably linked, and we have more control over how we express our health than we currently understand,” goop’s website reads.  

    In the past, according to Page Six, goop has faced some backlash for its “misleading” claims and it even paid $145,000 in civil penalties in September of last year in a case involving a vaginal egg. 

    Paltrow acknowledges the company’s mistakes, but says it never has claimed to be “prescriptive” with its recommendations. 

    “When we were young and not even monetizing the business and just sort of creating content, we didn’t necessarily understand anything about claims. We just thought, ‘Oh, this is a cool alternative modality, let’s write about it,’” she told the Times. “Of course we’ve made some mistakes along the way, but we’ve never been prescriptive. We’ve never said, ‘You should try this,’ or ‘This works.’ We’re just saying, ‘Wow, this is interesting, let’s have a Q and A with this person who practices this.’ And then that somehow gets translated into, ‘Gwyneth says you should do this.’”

    View the original article at thefix.com

  • Democrats Embrace Legalization In 2020 Primaries

    Democrats Embrace Legalization In 2020 Primaries

    A number of presidential hopefuls have been vocal about their experiences with marijuana and their desire to end its federal prohibition.

    Just a few election cycles ago, presidential candidates had to carefully craft their answers when asked whether they had ever tried marijuana. Heading into the 2020 campaign, however, many prominent Democratic candidates are vocally supporting marijuana legalization at the federal level. 

    Last week, U.S. Senator and presidential hopeful Cory Booker introduced legislation in the Senate that would legalize cannabis and expunge the records of people who have been convicted of federal marijuana-related expenses. Four other presidential candidates—Kamala Harris, Kirsten Gillibrand, Bernie Sanders and Elizabeth Warren—co-sponsored the bill. 

    The movement also has momentum outside Congress. Former Texas congressman and likely candidate Beto O’Rourke sent an email to supporters this week announcing his support for changes to federal marijuana policy, according to Reuters

    “We should end the federal prohibition on marijuana and expunge the records of those who were locked away for possessing it, ensuring that they can get work, finish their education, contribute to the greatness of this country,” O’Rourke wrote. 

    Senator Kamala Harris opposed an effort to legalize cannabis in California in 2010. (A later measure legalized recreational cannabis in the state.) However, she recently joked about marijuana use, riffing on President Bill Clinton’s infamous remark during the 1992 election that he had smoked marijuana, but did not inhale. 

    “I inhaled,” Harris said. “Half of my family’s from Jamaica. Are you kidding me?”

    Bernie Sanders has said that he tried cannabis, but didn’t like it and “nearly coughed my brains out.” He added, “It didn’t do a whole lot for me.”  

    Still, Sanders has been outspoken about the need to legalize cannabis. His home state of Vermont was the first in the nation to legalize cannabis through legislative action rather than a vote. 

    Too many lives are being destroyed. Hundreds of thousands of people get criminal records. You know why? Because they have smoked marijuana,” Sanders said this week. 

    Another candidate, former Colorado Governor John Hickenlooper, has been more cautious in his attitude toward marijuana reform. Despite the fact that he led a state that legalized marijuana early on, Hickenlooper has not called for federal legalization. However, he said that states should have the choice and federal banking laws need to change if that happens. 

    Polls show that most Americans—of both parties—favor legalizing cannabis. Among Democrats, three-quarters of voters feel that federal prohibition has to end. This cultural shift likely explains the enthusiasm from candidates, said Erik Altieri, executive director of the National Organization for the Reform of Marijuana Laws (NORML). 

    “The Democratic candidates are just acknowledging the practical and political reality—this is not only good policy, it’s good politics,” he said. 

    View the original article at thefix.com

  • Could Microdosing Psychedelics Treat Mood Disorders?

    Could Microdosing Psychedelics Treat Mood Disorders?

    A new study investigated whether low doses of psychedelic drugs could have an antidepressant effect. 

    Individuals in and out of the medical community have long been fascinated with psychedelic drugs and their short- and long-term mind-altering effects.

    Some people with depression believe the drugs have the ability to treat mental health disorders, and new research indicates they may be right.

    A study published in the journal ACS Chemical Neuroscience found that rats who received tiny doses of the psychedelic N,N-dimethyltryptamine (DMT) experienced an antidepressant effect, but no negative effects on their memories. 

    “Taken together, the data presented here suggest that subhallucinogenic doses of psychedelic compounds might possess value for treating and/or preventing mood and anxiety disorders,” study authors wrote. However, they warned that more research is needed into the safety and effectiveness of microdosing in humans.  

    “Despite the therapeutic potential of psychedelic microdosing, this practice is not without risks, and future studies need to better define the potential for negative neurobiological or metabolic repercussions,” they wrote. 

    The data suggests that people who extol the virtues of using psychedelics to treat depression and trauma may be on to something. 

    “These antidepressant-like and anxiolytic-like effects are consistent with the anecdotal human reports regarding psychedelic microdosing providing strong supporting evidence that psychedelic microdosing might actually have therapeutic potential,” study authors wrote. “Compounds capable of enhancing fear extinction learning in rodents, such as 3,4-methylenedioxymethamphetamine (MDMA) are excellent candidates for treating PTSD symptoms in humans.”

    With microdosing, an individual would receive enough of a drug to stimulate brain changes, but not enough to induce hallucinations. Finding the most effective amount may be time consuming, but researchers expressed “cautious optimism” that it could be done effectively.

    “The overall psychedelic microdosing load, which includes the amount of drug in each dose, the frequency of administration, and the length of treatment, is likely to be critical for achieving the beneficial effects of psychedelic microdosing without negative repercussions,” they wrote. 

    Proponents of psychedelics say that the drugs—even taken at high doses—can help alleviate symptoms of depression, addiction and other mental health conditions. In fact, during the 1950s and ’60s, psychedelics were a mainstream treatment option in Canada. Today, many people with addiction turn to ibogaine treatment, which is illegal in the United States, to help them heal from addiction and trauma. 

    Kevin Franciotti wrote for The Fix about his experience using ibogaine to treat his addiction: 

    “Each month throughout the year following my single dose treatment, an investigator called me to administer an outcomes interview measuring my addiction severity, and mailed me additional scales to fill out myself. At the end of my participation in the trial, ratings for depression, anxiety, and addiction severity had plummeted, reflecting the new lease on life ibogaine had brought me.”

    View the original article at thefix.com

  • Purdue Pharma Considers Bankruptcy Over OxyContin Lawsuits

    Purdue Pharma Considers Bankruptcy Over OxyContin Lawsuits

    If Purdue were to file for bankruptcy, it could “halt” the lawsuits that have been brought against the company by plaintiffs across the country.  

    Purdue Pharma, maker of the prescription opioid OxyContin, is reportedly exploring the option of bankruptcy to deal with the nearly 2,000 lawsuits brought against the company in the wake of the opioid epidemic.

    Purdue has been accused of engaging in aggressive and misleading marketing tactics to pressure doctors to prescribe far more OxyContin than was necessary, leading to a massive spike in addiction and overdose cases. The drug company has denied the allegations, but the lawsuits keep coming.

    If Purdue were to file for bankruptcy, it would “halt the lawsuits and allow Purdue to negotiate legal claims with plaintiffs under the supervision of a U.S. bankruptcy judge,” according to sources who spoke with Reuters.

    In a statement from Purdue, the company declined to comment on the likelihood of turning to bankruptcy over fighting the many lawsuits at their doorstep.

    “As a privately-held company, it has been Purdue Pharma’s longstanding policy not to comment on our financial or legal strategy,” the statement reads. “We are, however, committed to ensuring that our business remains strong and sustainable. We have ample liquidity and remain committed to meeting our obligations to the patients who benefit from our medicines, our suppliers and other business partners.”

    In response to the news, Connecticut Attorney General William Tong has vowed to continue pursuing the state’s suit against Purdue Pharma and its owners.

    “We will oppose any attempt to avoid our claims, and will continue to vigorously and aggressively pursue our claims against Purdue and the Sackler family,” he said.

    Filing for bankruptcy to help handle their legal troubles does not necessarily mean that the drug company is in financial trouble. Many other companies have chosen the same route when faced with lawsuits in the past, according to Fast Company.

    This includes the asbestos manufacturer Johns Manville and Dalkon Shield, the company that created a faulty IUD birth control implant and faced 6,000 lawsuits after thousands of women suffered infertility, ectopic pregnancies, and/or death.

    These two companies created a precedent that is now regularly used by companies faced with high profile controversies, including USA Gymnastics, Pacific Gas and Electric Co., and even the Catholic church.

    Companies that use bankruptcy in this manner can continue on with their business once everything is settled. Unfortunately, victims often receive less compensation than they would if the lawsuits had been settled by a standard civil court with a jury.

    “Corporations don’t want to risk a jury giving, say, $700 million to a cancer victim who used talcum powder every day,” writes Melissa Locker. “Settlements like that could quickly drive them into Chapter 7 bankruptcy, which is the kind where they have to liquidate their assets and potentially cease to exist. That’s why corporations cut victims off at the pass, so to speak, and file for Chapter 11, where the court will take a stoic, logical approach to paying out claims based on dollars and cents, not emotional pleas for the damage done to them.”

    View the original article at thefix.com

  • Deaths From Alcohol, Suicide & Overdose Reach Record High

    Deaths From Alcohol, Suicide & Overdose Reach Record High

    Suicide, drug overdose and alcohol now kill more than 150,000 Americans annually. 

    Deaths from suicide, drug overdose and alcohol have reached an all-time high in the United States. 

    Data from the Centers for Disease Control and Prevention (CDC) analyzed by two non-profit organizations revealed that deaths attributed to those causes rose 6% in 2017, USA Today reported.

    Those factors are now responsible for 46.6 deaths per 100,000—killing more than 150,000 people each year, according to U.S. News and World Report.

    In 2017, deaths from suicide rose 4%, double the pace of increase over the past decade. Deaths caused by synthetic opioids also skyrocketed, up 45%. However, five states saw decreases in deaths from suicide, overdose and alcohol. Those were Massachusetts, Oklahoma, Rhode Island, Utah and Wyoming.

    Loribeth Bowman Stein, of Milford, Connecticut, believes that social isolation is contributing to these co-called diseases of despair.

    She said, “We don’t really see each other anymore. We don’t share our hopes and joys in the same way, and we aren’t as available to one another, physically and emotionally, as we need to be. The world got smaller, but lonelier.”

    Kimberly McDonald, a licensed clinical social worker in Wisconsin lost her father to suicide, and says that she sees patients struggling with suicidal ideation and addiction every day. Often, they don’t get the support that they need to heal. 

    “We are a society that criticizes and lacks compassion, integrity, and empathy. I work daily with individuals who each have their own demons,” she said. 

    However, Benjamin Miller, a psychologist and chief strategy officer at the Well Being Trust, said that people need to avoid the temptation to explain away these alarming statistics. 

    He said, “It’s almost a joke how simple we’re trying to make these issues. We’re not changing direction, and it’s getting worse.”

    The Well Being Trust calls for policy changes, such as restricting access to firearms and medications that can be deadly for someone looking to end their life. In addition, the trust calls for more funding for programs that support resiliency in kids, address childhood trauma, and provide treatment for addiction.

    All of these efforts, Miller said, can help save lives. Progress has been made in these areas, but there is need for more work, Miller said. 

    “It is important to see hope in the slowing of rates—but it’s not nearly enough. We should not be satisfied at all. Too many of us are dying from preventable causes.”

    Overall, the suicide rate has increased 33% since 1999. Rural states including West Virginia, New Mexico, Ohio, Alaska and New Hampshire have the highest suicide rates. 

    View the original article at thefix.com

  • FDA Approves Ketamine-Derived Spray for Depression

    FDA Approves Ketamine-Derived Spray for Depression

    The newly approved esketamine nasal spray will be administered under a doctor’s supervision at approved and certified treatment centers. 

    Clearing the way for the first major change to depression treatment in decades, the FDA approved a ketamine-derived nasal spray that can be used to rapidly treat depression on Tuesday (March 5). 

    “Thank goodness we now have something with a different mechanism of action than previous antidepressants,” Dr. Erik Turner, who teaches psychiatry at Oregon Health & Science University, told The New York Times

    In recent years ketamine has garnered a lot of attention from the medical community because it quickly and effectively relieves depression and suicidal ideation. Ketamine treatments have become popular, but until now the drug, which is approved as an anesthetic, has been used off label. This means treatments are unregulated and not covered by insurance. 

    The medication approved this week is esketamine, which contains a part of the ketamine molecule. It was developed by Janssen Pharmaceuticals and will be sold under the name Spravato.

    Since up to a quarter of depression patients don’t get relief from current antidepressants, people in the mental health community are happy to see a new option for treatment. However, Turner and others are cautious in their excitement. 

    “I’m skeptical of the hype, because in this world it’s like Lucy holding the football for Charlie Brown: Each time we get our hopes up, the football gets pulled away,” Turner said. 

    Under the FDA recommendations, esketamine will be used in conjunction with an established antidepressants. Patients will get treatment twice a week for four weeks, and then as needed.

    Although the nasal spray is non-invasive, it must be administered in a doctor’s office where patients can be observed for two hours. The use of esketamine could give patients fast relief from their symptoms, which is important since traditional antidepressants can take weeks to become effective. 

    Dr. Todd Gould, a psychiatrist at the University of Maryland School of Medicine who has done ketamine research, said that the potential for fast-acting relief is appealing, even if ketamine doesn’t completely revolutionize depression treatment. 

    “These are exciting times, for sure,” he said. “We have drugs that work rapidly to treat a very severe illness.”

    Vanderbilt University professor Steven Hollon agreed. 

    “We’ve had nothing new in 30 years, so if this drug is an effective way to get a more rapid response in people who are treatment resistant, and we can use it safely, then it could be a godsend.”

    The FDA fast-tracked esketamine’s approval process. Although the drug has been used safely as an anesthetic for decades, medical professionals will be carefully monitoring its use in the mental health space, researcher James Stone told Newsweek last year. 

    “Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don’t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing. Further studies are needed to address these questions.”

    View the original article at thefix.com

  • UFC Launches Opioid Awareness Campaign

    UFC Launches Opioid Awareness Campaign

    In the video, UFC president Dana White highlights statistics about the toll taken by the opioid crisis and offers resources for those in need of help. 

    The mixed martial arts organization Ultimate Fighting Championship (UFC) has joined in the fight against the national opioid crisis by launching its own public service campaign to heighten awareness about the impact of opioid dependency.

    The campaign, which kicked off in Las Vegas on March 2, 2019, featured UFC President Dana White, as well as the Substance Abuse and Mental Health Services’ (SAMHSA) National Helpline.

    The campaign fulfills the UFC’s 2018 commitment to create a public service campaign as part of its relationship with the Trump Administration’s Initiative to Stop Opioid Abuse.

    In a press release, UFC stated that future announcements will feature UFC athletes and take advantage of the company’s sizable social media audience of 75 million followers and widely viewed live events to “spread the message of prevention, treatment, and recovery related to opioid addiction.”

    The video featuring White premiered before the UFC 235: Jones vs. Smith event on March 2.

    In October 2018, the UFC was among a group of lawmakers and representatives from more than 20 major stateside companies, including Amazon, Facebook and Blue Cross Blue Shield, to appear at a White House ceremony where President Trump signed into law the SUPPORT for Patients and Communities Act, which was intended to provide help for opioid treatment and recovery initiatives.

    White, who spoke at the Republican National Convention in support of Trump’s bid for the White House, pledged his company’s assistance in helping to combat the epidemic. 

    “Opioid addiction does not discriminate,” said White at the 2018 ceremony. Millions of Americans are impacted by this tragic crisis. UFC is committed to helping President Trump in the fight to end opioid abuse.” At the time of the ceremony, UFC announced that it would roll out its public service campaign before the end of 2018.

    In the video, White highlights statistics about the toll taken by the opioid crisis – drug overdoses are currently the leading cause of death among Americans under the age of 50, and two-thirds of drug overdose deaths are caused by opioids – which is followed by the National Helpline number and SAMHSA’s web address.

    View the original article at thefix.com

  • Black Balloon Day Pays Tribute To Lives Lost To Addiction

    Black Balloon Day Pays Tribute To Lives Lost To Addiction

    Families and loved ones across the country are taking part in the growing Black Balloon movement which memorializes lives lost to addiction.

    Diane Hurley, a Peabody, Boston resident, lost both her son-in-law, Greg, and her son, Sean, to overdoses. Hurley wanted to find a way to both memorialize the two men and remind people that drug addiction is a crisis.

    Hurley, her son, and her two daughters hung black balloons outside of their homes on the first anniversary of Greg’s death. Greg was a father of four and 38 years old at the time of his passing. “I thought of death,” Diane Hurley told The Daily Item. “And then I thought of black.”

    The simple gesture turned into Black Balloon Day, a national movement every March 6th. Hurley and her children spread the word online about displaying black balloons in 2016, and over 42,000 people responded and joined the memorial.

    Every year on the 6th, families around the country send photos of the black balloons they have anchored to float outside, alongside the hashtag #BlackBalloonDay.

    “I had this vision that you wouldn’t be able to escape the balloons, just like you can’t escape this epidemic,” she told The Salem News, explaining how addiction doesn’t discriminate and touches everyone.

    “In one way or another, I feel like everyone I talk to has dealt with this pain,” Hurley said. “I work in a nursing home and, including myself, there are seven or eight women who have all lost a child or a sibling to addiction.”

    And this year, Hurley tragically lost her son Sean to addiction, after being sober for five years. The recent death of a friend had unmoored him and although he was doing well, according to Hurley, he overdosed and died at age 30. He’d had a second child on the way.

    Hurley wrote her son’s obituary transparently, hoping to spread awareness. “When he used to tell me he had a disease, I would tell him not to say that and not to compare himself to people who actually have diseases, like cancer. I never really understood it.” 

    “I learned that it wasn’t a choice, it’s a disease,” said Hurley. “When people say: ‘They made this choice, it’s their problem,’ most of them do not understand that many people who suffer with addiction have some sort of underlying health issues.”

    Hurley and the Black Balloon movement are now a nonprofit organization and will be raising money to put Narcan in public bathrooms, one of the most common places for overdoses to occur.

    “We can’t be ashamed about addiction,” said Hurley. “We need to talk about it. It’s killing a whole generation of people and we have to do something.”

    View the original article at thefix.com

  • Dentists Need To Make Sweeping Changes To Opioid Prescribing

    Dentists Need To Make Sweeping Changes To Opioid Prescribing

    Dentists have decreased the amount of opioid prescriptions they write by nearly 500,000—but some believe it’s not enough.

    Three years ago, P. Angela Rake decided to make a major change at her oral surgery practice.  

    “After the loss of Prince, I just drew a line in the sand that I’m going to change my prescribing practices,” Rake said, according to The Chicago Tribune. In just two years, she reduced the amount of opioids she was prescribing by 70%. 

    It wasn’t just the death of the superstar that moved her. Rake had also seen her own brother get hooked on opioids that he was given during cancer treatment. Having seen firsthand the dangers of opioid addiction, she knew that she couldn’t continue to prescribe opioids to her patients in the usual manner. 

    Today, she only prescribes opioids when absolutely necessary. The patients who do need opioids get few pills and lower doses. Rake now says she feels like the opioid industry deceived her. 

    “When these drugs came into being routinely prescribed, the industry-funded message we were being told was that the risk of addiction was less than 1 percent. We were misled.”

    The truth is that the risk of addiction for young people given opioids after oral surgery is closer to 6%. Now, more dentists are becoming aware of the danger of these pills for the youngest patients, said Andrew Kolodny, co-director of opioid treatment research at Brandeis University.

    “Dentists and oral surgeons are the No. 1 prescribers of opioids to teenagers. What’s so disturbing is that it’s so unnecessary. These are kids who could have gotten Advil and Tylenol,” he said. “It’s almost a rite of passage in the United States having your wisdom teeth out. The aggressive prescribing of opioids to adolescents may be why we’re in an epidemic.”

    Dentists have decreased the amount of opioid prescriptions they write by nearly half a million, from 18.5 million in 2012 to 18.1 million in 2017. However, that’s a far cry from the 70% reduction that Rake made, and some within the industry say it is not enough. 

    Romesh Nalliah, who teaches at the University of Michigan School of Dentistry and has studied opioid prescribing among dentists, said that dentists are concerned about customer satisfaction, and sometimes that relies on doling out opioids. 

    “Dentists are also business owners. They don’t want patients to say, ‘Dr. Nalliah did my extraction, and now I’m in agony,’” Nalliah said. Despite that, he has now changed the way that he prescribes opioids, and urges others in the field to do the same. 

    He said, ”I don’t want to be responsible for someone becoming addicted to opioids. I personally think we can cut opioid prescribing in dentistry to less than half of what we do now.”

    View the original article at thefix.com

  • Wearable Sensor Could Point To Anxiety, Depression In Kids

    Wearable Sensor Could Point To Anxiety, Depression In Kids

    New tech may help children better identify their own feelings.

    Whether or not a child suffers from an internalizing disorder like depression or anxiety may soon be identifiable through a wearable sensor, new research indicates.  

    According to PsyPost, a recent study put the sensors to the test. The study involved 63 children ages 3 to 8, both with and without internalizing disorders. The children wore a motion sensor which tracked their movement, and a machine learning algorithm then analyzed those movements. 

    Study author Ellen W. McGinnis, a postdoctoral fellow at the University of Vermont Medical Center, says children struggle to identify their own feelings, so the sensor may help do so. 

    “Young children who suffer from anxiety and depression often have a lot of difficulty understanding and communicating their suffering—and for parents, it’s really difficult to read inner emotions of someone who doesn’t even understand themselves,” she said.  

    “This is also a large problem, with up to 1 in 5 children experiencing an internalizing disorder during childhood, that can lead to increased risk for serious health problems like chronic anxiety and depression, substance abuse, and suicide, later in life if left untreated,” added study co-author Ryan S. McGinnis, an assistant professor at the University of Vermont. 

    During the study, children were taken into a “dimly lit” room. A research assistant then made statements meant to increase the children’s anticipation. The statements included things like, “I have something to show you,” and, “Let’s be quiet so it doesn’t wake up.”

    The back of the room housed a covered terrarium. With the children in the room, the research assistant then pulled out a fake snake, assuring the children the assistant was allowed to play with the reptile. 

    This exercise and the sensors led researchers to determine that the children in the study with disorders like anxiety and depression were more apt to turn away before the snake was taken out. The algorithm from the machine did pick up on some variations between children with internalizing disorders versus those without—in fact, it was 81% accurate. 

    “Feasible objective screening of child anxiety and depression in young children is possible using wearable technology and is proving to be very sensitive—meaning we can find those previously overlooked kids and connect them to the services they need,” Ellen McGinnis told PsyPost.

    “Hopefully people will start to see technologies like these being deployed during their children’s pediatric well visits in the coming years,” Ryan McGinnis added.

    Though the results are promising, as with most small studies, researchers say a larger sample is needed to prove their results further.

    “A big caveat is that, although our results are intriguing and promising, we need to replicate them in a much larger, more diverse sample,” Ellen McGinnis told PsyPost. “In so doing, we’d like to partner with pediatricians to ensure that the resulting technology can easily fit within the workflow of a standard pediatric well visit.”

    View the original article at thefix.com